LSE - Delayed Quote USD

Roche Holding AG (0TDF.L)

39.56
+1.42
+(3.72%)
As of May 20 at 4:51:03 PM GMT+1. Market Open.
Loading Chart for 0TDF.L
  • Previous Close 38.14
  • Open 39.56
  • Bid --
  • Ask --
  • Day's Range 39.56 - 39.56
  • 52 Week Range 32.09 - 40.26
  • Volume 1,330,000
  • Avg. Volume 352
  • Market Cap (intraday) 269.439B
  • Beta (5Y Monthly) 0.17
  • PE Ratio (TTM) 0.19
  • EPS (TTM) 2.07
  • Earnings Date Jul 24, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.

www.roche.com

103,249

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Recent News: 0TDF.L

View More

Performance Overview: 0TDF.L

Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

0TDF.L
12.96%
MSCI WORLD (^990100-USD-STRD)
4.43%

1-Year Return

0TDF.L
19.76%
MSCI WORLD (^990100-USD-STRD)
11.27%

3-Year Return

0TDF.L
0.00%
MSCI WORLD (^990100-USD-STRD)
45.79%

5-Year Return

0TDF.L
0.00%
MSCI WORLD (^990100-USD-STRD)
86.68%

Compare To: 0TDF.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0TDF.L

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.27%

  • Return on Assets (ttm)

    12.75%

  • Return on Equity (ttm)

    26.47%

  • Revenue (ttm)

    62.39B

  • Net Income Avi to Common (ttm)

    8.28B

  • Diluted EPS (ttm)

    2.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    17.33B

  • Total Debt/Equity (mrq)

    100.60%

  • Levered Free Cash Flow (ttm)

    13.67B

Research Analysis: 0TDF.L

View More

Company Insights: 0TDF.L

Research Reports: 0TDF.L

View More

People Also Watch